Clinical Trials Logo
  1. Home
  2. Delayed Graft Function
  3. NCT04005469

Safety and Efficacy of Treprostinil (Remodulin®) In Reducing Ischemia-Reperfusion Injury During Kidney Transplantation

Delayed Graft Function Clinical Trial

Official title:
A Phase I/II Study Evaluating the Preliminary Safety and Efficacy of Treprostinil (Remodulin®) In Reducing Ischemia-Reperfusion Injury During De Novo Adult Kidney Transplantation

Clinical Trial Summary

The objectives of this study are to test the preliminary safety and efficacy of a two-day peri-operative course of treprostinil in reducing ischemia-reperfusion injury in adult patients receiving a deceased donor kidney transplantation. Treprostinil, a prostacyclin analog, is expected to facilitate the restoration of blood supply to the revascularized kidney graft via its vasodilatory actions, well characterized protective effects, and longer elimination half-life. These properties and actions of treprostinil make it a strong drug candidate to reduce kidney graft dysfunction during kidney transplantation. An anticipated 20 participants undergoing deceased donor kidney transplant will be hospitalized and intensively monitored during an entire two-day Treatment Phase. An IV infusion using a dedicated central venous line will be used to administer treprostinil commencing approximately 2-3 hours before transplantation of the kidney graft and will continue for approximately 48 hours after completion of the transplant surgery. The primary endpoints include the safety and efficacy of treprostinil, with secondary endpoints including the evaluation of both biochemical and clinical endpoints post-transplantation.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT04005469
Study type Interventional
Source Rhode Island Hospital
Contact Reginald Y Gohh, MD
Phone 401-444-3284
Email RGohh@Lifespan.org
Status Recruiting
Phase Phase 1/Phase 2
Start date November 13, 2020
Completion date June 30, 2026
View Details
See also
  Status Clinical Trial Phase
Withdrawn NCT02312115 - Delayed Renal Allograft Function and Furosemide Treatment Phase 2
Completed NCT02134314 - C1INH Inhibitor Preoperative and Post Kidney Transplant to Prevent DGF & IRI Phase 1/Phase 2
Completed NCT02346968 - Evaluation of CAF22 After Renal Transplantation
Completed NCT01794663 - Placebo-Controlled Study to Evaluate the Safety and Efficacy of OPN-305 in Preventing Delayed Renal Graft Function Phase 2
Completed NCT00298181 - YSPSL for Prevention of Delayed Graft Function Part A Phase 1/Phase 2
Not yet recruiting NCT05166460 - Novel Cooling Device for the Elimination of Warm Ischemia During Renal Transplantation N/A
Recruiting NCT03071536 - Furosemide Stress Test Predicting Early Graft Function in Kidney Transplantation N/A
Not yet recruiting NCT05513807 - Graft Acute Kidney Injury: Vitamin B3 to Facilitate Renal Recovery In the Early Life of a Transplant Phase 3
Completed NCT01848249 - Deceased Donor Biomarkers and Recipient Outcomes
Active, not recruiting NCT02474667 - Reduce the Severity of DGF in Recipients of a Deceased Donor Kidney Phase 3
No longer available NCT02026934 - CliniMACS® CD34+ Reagent System for Expanded Access Use N/A
Terminated NCT00217152 - A Kidney Transplant Study to Look at the Effects of Taking Fixed Doses of CellCept Versus Taking Doses of CellCept Based on the Concentration of CellCept in the Blood When Taking Full or Reduced Dose Calcineurin Inhibitors Phase 4
Recruiting NCT05430620 - Intermittent Versus Continuous Surface O2 During HMP of DCD Kidneys Phase 3
Completed NCT03864926 - Envarsus in Delayed Graft Function (E-DGF) Phase 4
Recruiting NCT06367205 - Norepinephrine Infusion Combined With Goal-directed Fluid Therapy in Patients Undergoing Kidney Transplantations N/A
Completed NCT02610296 - QPI-1002 for Prevention of Delayed Graft Function in Recipients of an Older Donor Kidney Transplant Phase 3
Active, not recruiting NCT02568696 - Intra-graft Coagulation Events in Clinical Renal Transplantation and Delayed Graft Function
Recruiting NCT01837043 - Early Conversion From CNI to Belatacept in Renal Transplant Recipients With Delayed and Slow Graft Function Phase 2
Terminated NCT01878786 - A Pilot Study Comparing the Safety and Efficacy of Everolimus With Other Medicines in Recipients of ECD/DCD Kidneys Phase 2/Phase 3
Active, not recruiting NCT01395719 - Context - Remote Ischemic Conditioning in Renal Transplantation - Effect on Immediate and Extended Kidney Graft Function N/A